Halozyme Receives FDA OK for Contract Manufacturing Facilities
Halozyme Therapeutics Inc., a biopharmaceutical company headquartered in San Diego, California, reports that the
Hylenex recombinant is a tissue permeability modifier indicated as an adjuvant to increase the dispersion and absorption of other injected or subcutaneously infused drugs, to facilitate subcutaneous fluid administration, and in subcutaneous urography. Hylenex recombinant is contraindicated in patients with a known hypersensitivity to recombinant human hyaluronidase or any excipient used to make the drug.
Source: Halozyme Therapeutics